Until now, patients taking the new class of GLP-1 drugs have had to choose from either a weekly injection that's stored in the refrigerator, like Ozempic, Wegovy, or Zepbound, or swallow a once-daily pill that requires patients to take it first thing in the morning on an empty stomach with a small glass of water (Rybelsus or Wegovy pill, from Novo Nordisk)
If you want better outcomes, focus on the boring details
While both drugs affect appetite regulation and weight reduction through different biological pathways, combining them involves real clinical considerations that deserve careful attention before starting any regimen
On April 1, 2026, the FDA approved Eli Lillys FOUNDAYO (orforglipron) , the second oral GLP-1 approved for obesity, and arguably the one with the more patient-friendly convenience profile